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Summary Altered expression of the retinoblastoma (RB) tumour-suppressor gene product (pRB) has been
detected in sporadic bone and soft-tissue sarcomas. Earlier studies, analysing small cohorts of sarcoma
patients, have suggested that these alterations are more commonly associated with high-grade tumours,
metastatic lesions and poorer survival. This study was designed to re-examine the prevalence and clinical
significance of altered pRB expression in a large and selected group of soft-tissue sarcomas from 174 adult
patients. Representative tissue sections from these sarcomas were analysed by immunohistochemistry using a
well-characterised anti-pRB monoclonal antibody. Tumours were considered to have a positive pRB
phenotype only when pure nuclear staining was demonstrated, and cases were segregated into one of three
groups. Group 1 (n = 36) were patients whose tumours have minimal or undetectable pRB nuclear staining
(<20% of tumour cells) and were considered pRB-negative. Patients with tumours staining in a heterogeneous
pattern (20-79% of tumour cells) were classified as group 2 (n = 99). The staining of group 3 (n = 39) was
strongly positive with a homogeneous pRB nuclear immunoreactivity (80-100% of tumour cells). pRB
alterations were frequently observed in both low- and high-grade lesions. Altered pRB expression did not
correlate with known predictors of survival and was not itself an independent predictor of outcome in the
long-term follow-up. These findings support earlier observations that alterations of pRB expression are
common events in soft-tissue sarcomas; nevertheless, long-term follow-up results indicate that altered patterns
of pRB expression do not influence clinical outcome of patients affected with soft-tissue sarcomas. It is
postulated that RB alterations are primary events in human sarcomas and may be involved in tumorigenesis or
early phases of tumour progression in these neoplasias.
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The prognosis of patients with soft-tissue sarcomas has tra-
ditionally been determined by clinical and histopathological
features of the tumour such as grade, size and depth. A
number of staging systems have been developed which
broadly categorise patients into groups of different survival
potential (Russel et al., 1977; Beahrs et al., 1988; Shiu and
Brennan, 1989). To date there is no universally accepted
system for the staging of soft-tissue sarcomas, although the
most widely employed is the AJCC (Beahrs et al., 1988).
Recent advances in the recognition and understanding of
molecular genetic events occurring in the pathogenesis of
human sarcomas have resulted in attempts to define new
prognostic markers.
Children affected with the hereditary form of retinoblas-
toma often develop a second malignancy several years after
successful treatment of their primary tumour (Abramson et
al., 1984). Most of these secondary neoplasms are bone or
soft-tissue sarcomas (Hansen et al., 1985). In contrast,
secondary neoplasms are uncommon in patients with the
sporadic form of the disease. Knudson proposed that
retinoblastoma developed as the result of two mutations
inactivating both alleles of a single gene (Knudson, 1971).
The RB gene maps to chromosome 13, band 13q14, and it
encodes for a 110 kDa nuclear phosphoprotein (Friend et al.,
1986; Fung et al., 1987; Lee et al., 1987). pRB is phos-
phorylated in a cell cycle-dependent manner; underphos-
phorylated pRB products are the predominant form in G,,
exerting a growth-suppressive effect (Buchkovich et al., 1989;
DeCaprio et al., 1989; Xu et al., 1991). Since pRB does not
seem to possess sequence-specific DNA-binding activity, it is
postulated that the negative regulatory effect of underphos-
phorylated pRB is through complex formation with DNA-
binding proteins (DeFeo-Jones et al., 1991), such as the
transcription factor E2F (Chepallan et al., 1991). In addition,
pRB appears to be involved in the differentiation programme
of certain cell lineages, since homozygous mutant RB mouse
embryos die during embryonic development with major
derangements of the central nervous system and erythro-
poiesis (Jacks et al., 1992; Lee et al., 1992). In recent years
numerous lines of evidence have confirmed the concept that
the RB gene is the prototypical tumour-suppressor gene
(Huang et al., 1988; Sumegi et al., 1990). RB mutations and
altered patterns of pRB expression have been detected in
other malignancies, including soft-tissue sarcomas (Cance et
al., 1990; Stratton et al., 1990; Wunder et al., 1991), acute
myelogenous leukaemia (Kornblau et al., 1992), breast cancer
(Lee et al., 1988; Varley et al., 1989), bladder carcinomas
(Cairns et al., 1991; Cordon-Cardo et al., 1992; Logothetis et
al., 1992) and small-cell carcinoma of the lung (Harour et al.,
1988; Hensel et al., 1990).
We previously studied a group of 44 primary high-grade
bone and soft-tissue sarcomas of all age groups using
immunohistochemistry, and observed a 70% incidence of
altered pRB expression (Cance et al., 1990). Patients whose
tumours had strong homogeneous expression of pRB had
significantly better survival than patients with heterogeneous
or absent expression of the pRB gene product. Given the
potential clinical significance of these findings, we have
extended our original study and analysed a larger cohort of
174 adult soft-tissue sarcomas for pRB expression. In the
present analysis, all bone and paediatric tumours were ex-
cluded; however, specimens from metastatic sarcomas were
included but were analysed separately.
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Tissue
The tumour samples used in this study were obtained fresh
following surgical resection, embedded in a cryopreservative
solution (OCT compound, Miles, Elkhart, IN, USA), and
stored at -70C until needed. Formalin-fixed sections of
each specimen were stained with haematoxylin-eosin and
examined microscopically. One pathologist (JMW) re-
reviewed the histopathological diagnosis, tumour grade and
quality of the tissue of 280 sarcomas. All paediatric, bone
and tumours of uncertain histopathology were excluded. A
total of 174 tumours met the inclusion criteria and were used
for analysis.
Patients
Clinical information on every adult patient admitted to
Memorial Sloan-Kettering Cancer Center from July 1982 to
the present has been maintained in a computerised prospec-
tive database. Precise clinical follow-up information was
available on 172 of the 174 patients, including the type of
treatment and follow-up time as well as disease status.
Tumour characteristics including tumour size, site, histo-
logical subtype and grade were also recorded.
Monoclonal antibodies and immunohistochemistry
Immunohistochemical analyses were performed utilising
mouse monoclonal antibody Rb-PMG3-245 (IgG, subclass)
as the primary antibody. This antibody was generated by
immunising mice with the TrpE/Rb fusion protein and it has
been shown to specifically recognise the 1100 kDa RB gene
product (Cordon-Cardo and Richon, 1994). A non-specific
IgG, mouse monoclonal antibody was used in all experiments
as a negative antibody control. Normal tissue known to
express the RB-encoded protein, as well as a pRB-positive
(T24, bladder cancer) and a pRB-negative (Y79, retinoblas-
toma) cell line, were used as controls.
The avidin-biotin complex immunoperoxidase technique
was the method used for the present study. Briefly, frozen
tissue blocks were cut to 61tm thin sections placed on micro-
slides and formalin fixed. The Rb-PMG3-245 antibody (final
concentration, 10 g ml-') and the non-specific negative con-
trol antibody (used at the same concentration) were applied
to consecutive sections of the same tumour. After extensive
washing, tissues were incubated with biotinylated horse
antimouse secondary antibodies (Vector Laboratories, Bur-
lingame, CA, USA) for 30 min at a concentration of 1:100,
followed by avidin-biotin-peroxidase complexes (Vector
Laboratories) at 1:25 dilution. Diaminobenzidine was used as
the final chromogen and ethyl green as the nuclear counter-
stain.
Statistical methods
Fisher's exact test was used to assess the association between
clinicopathological factors and altered patterns of pRB
(Mehta and Patel, 1983). The Kaplan-Meier method (Kaplan
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and Meier, 1958) was used to estimate the survival functions.
All non-tumour-related deaths were censored in the Kap-
lan-Meier analysis. The log-rank test (Peto et al., 1977) was
used to compare differences in survival between groups of
patients.
Results
The histopathological and relevant clinical characteristics of
this group of soft-tissue sarcomas are summarised in Table I.
Most of the specimens analysed were large, high-grade
primary tumours. Thirty-three cases (19%) were metastatic
lesions. Liposarcomas and leiomyosarcomas represented the
most common histopathological subtypes.
Nuclear staining for pRB was typically observed in
endothelial cells, lymphocytes and fibroblasts. We considered
tumour samples studied to have a positive pRB phenotype
only when pure nuclear staining was demonstrated. Cytoplas-
mic staining was occasionally observed in some sarcomas
analysed. The intensity and pattern of pRB nuclear staining
with the Rb-PMG-245 antibody was used to separate the
cases into one of three groups. Group 1 (n= 36) were
patients whose tumours had minimal or undetectable nuclear
staining (<20% of tumour cells) and were considered pRB
negative. Patients with tumours staining in a heterogeneous
pattern (20-79% of tumour cells) were classified as group 2
(n = 99). The staining of group 3 (n = 39) was strongly
positive with a homogeneous pRB nuclear immunoreactivity
Histopathology
Liposarcoma
Leiomyosarcoma
Malignant fibrou
Fibrosarcoma
Synovial cell sarc
MPNST
Rhabdomyosarco
Other
Table I Tumour characteristics
Number
62
48
Lshistiocytoma 16
11
coma 9
12
ima 2
14
Grade
High
Low
Unknown
Size
< = 5 cm
> = 5 cm
Unknown
Depth
Superficial
Deep
Undetermined
Presentation status
Primary
Local recurrence
Distant recurrence
Unknown
141
32
I
37
130
7
8
133
33
108
31
33
2
Per cent
35.6
27.6
9.2
6.3
5.2
6.9
1.1
8.0
81.0
18.4
0.6
21.3
74.7
4.0
4.6
76.4
19.0
62.1
17.8
19.0
1.1
MPNST, malignant peripheral nerve sheath tumour.
Table II Primary adult soft tissue sarcomas: pattern of Rb expression by
histopathology
Rb Rb Rb Per cent
Histopathology n negative heterogeneous positive altered
Liposarcoma 42 7 29 6 86
Leiomyosarcoma 25 10 9 6 76
Malignant fibrous histiocytoma 10 3 5 2 80
Fibrosarcoma 7 1 2 4 43
Synovial cell 6 0 2 4 33
MPNST 8 1 5 2 75
Rhabdomyosarcoma 2 0 2 0 100
Other 8 1 4 3 63
MPNST, malignant peripheral nerve sheath tumour.iRBexpression inadultsot-tissuesarcomas RB expression in adult MS Karpeh etal
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(80- 100% of tumour cells). The majority of the tumours
stained in a heterogeneous pattern (57%), while 21% of the
cases were negative and 22% were clearly positive for the
anti-pRB antibody. Possible associations between clinical fac-
tors and pRB status were assessed using the Fisher's exact
test. The degree of pRB positive staining did not correlate
with important clinical factors analysed, such as grade, size,
depth and status at presentation.
Expression ofthe RBprotein in primary sarcomas
A total of 108 primary sarcomas were studied. Alterations in
pRB expression occurred in 81 of 108 cases (75%) on the
basis of undetectable or heterogeneous staining. The level of
RB gene product expression for a given histopathological
type is shown in Table II. No individual histopathological
type stood out as having a higher propensity for altered pRB
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expression. The remaining 27 tumours demonstrated strong
positive staining. Eighty-eight of these primary sarcomas
were high grade, and 67 of these cases (76%) demonstrated
altered pRB expression. Most low-grade sarcomas also
revealed heterogeneous or undetectable pRB staining, with 22
of 32 tumours (70%) showed altered pRB. Comparisons were
made between pRB expression status and tumour grade, size
and depth. No significant relationships were observed.
Expression ofthe RBprotein in metastatic and recurrent
sarcomas
Immunohistochemical staining of metastatic tumours
revealed that 27 of 33 cases (82%) had altered pRB expres-
sion. Similarly, 27 of 31 locally recurrent lesions (87%) had
undetectable or minimally positive staining tumour cells for
Rb-PMG3-245 antibody.
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Figure 1 (a) Kaplan-Meier survival curves of all adult patients with soft-tissue sarcomas stratified by the degree of pRB
expression in their tumours. 0, 0-19% (35 patients, 19 censored); 0, 20-79% (99 patients, 57 censored); A, 80-100% (36
patients, 22 censored). (b) Kaplan-Meier survival curves of adult patients presenting with primary soft-tissue sarcomas stratified on
the basis of pRB expression in their tumours. 0, 0-19% (23 patients, 14 censored); 0, 20-79% (58 patients, 37 censored); A
80-100% (27 patients, 16 censored). (c) Kaplan-Meier survival curves of adult patients presenting with primary high-grade
soft-tissue sarcomas stratified on the basis of pRB expression in their tumours. 0, 0-19% (21 patients, 12 censored); 0, 20-79%
(46 patients, 26 censored); A 80-100% (21 patients, 11 censored). Tick mark (1) indicates last follow-up.
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Table III Demographics of primary soft tissue sarcomas
Total Rb Rb Rb
n = 106 negative heterogeneous positive
Median age 58 63 59 52
Male/female 59/47 13/13 34/21 12/13
Median follow-up 34 months 34 months 35 months 30 months
Survival at 2 years 62% 58% 67% 62%
Survival analysis
The median follow-up time for the entire study population
was 37 months, with a mean of 39 months. Patients in
groups 1, 2 and 3 had median follow-ups of 30, 35 and 34
months respectively. The survival of patients in these groups
was compared using the Kaplan-Meier method. Figure la
illustrates the tumour-specific survival stratified by pRB
staining patterns. There was no difference in survival between
the three groups at long term follow-up.
Tumour grade is typically a dominant factor influencing
survival. When we divided the 172 patients into two groups
based on grade (high vs low), the survival was significantly
different between these two categories (P<0.01). Survival
was then analysed based on pRB status and tumour grade.
Tumours of the same grade had similar survival characteris-
tics regardless of pRB status. The log-rank results were not
significant.
Survival analysis ofprimary sarcomas
The demographics of this group are shown in Table III. The
above analysis included 64 patients who presented with either
local recurrences or distant metastases, which may potentially
bias survival. The Kaplan-Meier curves in Figure lb repre-
sent the survival of patients who presented with primary
tumours stratified by their pattern of Rb-PMG3-245
antibody immunostaining. Survival was very similar for each
group. To eliminate the possible influence of tumour grade,
survival for all primary high-grade lesions was also
independently analysed. There was no statistical difference in
survival between the two groups at long-term follow-up
(Figure lc).
Discussion
Sarcomas often present as secondary neoplasms in patients
with the hereditary form of retinoblastoma (Hansen et al.,
1985; Friend et al., 1986). This early observation led to
questions concerning the potential role of RB in the
tumorigenesis of sporadic bone and soft-tissue sarcomas.
Subsequent studies revealed that RB mutations also occur in
sporadic sarcomas. Stratton et al. (1989) found homozygous
RB deletions in only 3 of 63 sarcomas analysed, and loss of
heterozygosity in 5 of 22 informative cases. Reissmann et al.
(1989) also found RB deletions in three of nine osteosar-
comas and 4 of 29 soft-tissue sarcomas. These studies were
conducted utilising restriction fragment length polymorphism
and Southern blot assays in order to identify RB gene muta-
tions. Subtle alterations, sufficient to decrease or abort RB
gene expression, are usually undetectable when using these
techniques and may explain the lower frequency of RB alter-
ations reported.
Methods which are guided to the analysis of gene expres-
sion are known to be more sensitive in detecting underlying
RB alterations. Wunder et al. (1991), using Northern blot
analysis, demonstrated an association between tumour grade
and altered RB transcripts. They found low to undetectable
RB mRNA levels in 10 of 25 high-grade bone and soft-tissue
sarcomas analysed. In contrast, only 1 of 11 low-grade sar-
comas and none of the four lipomas studied showed altered
RB transcripts.
In a preliminary study from our group and for the present
report, expression ofpRB was assessed by the Rb-PMG3-245
monoclonal antibody and immunohistochemistry. This tech-
nique allows correlation of expression with microanatomic
features and can identify the degree of heterogeneity and
range of intensity of expression within a tumour. In our
earlier series of 56 non-selected soft-tissue sarcomas, we
showed that pRB was undetectable or heterogeneously exp-
ressed in 70% of the primary high-grade sarcomas, as well as
in all metastatic lesions analysed (Cance et al., 1990). In the
present study similar results were obtained. Briefly, primary
high-grade lesions showed pRB alterations in 67 of 88 (76%)
cases, while local recurrent and metastatic tumours had
altered expression in 27 of 31 (87%) and 27 of 33 (82%)
cases respectively. Nevertheless, we also observed that 22 of
32 (70%) low-grade sarcomas studied displayed either
heterogeneous or undetectable pRB expression.
The basis for the heterogeneous pattern of pRB immuno-
staining observed on tumour cells in clinical samples may be
interpreted as follows. First of all, it could be a genuine
biological phenomenon of identifying two distinct tumour
clones, one having the wild-type protein and another har-
bouring a mutation. On the other hand, it may be caused by
limitations of the assay and reagents utilised. For example, it
could reflect pRB variations that occur during cell cycle,
either intercellular differences in the level of bound vs
unbound pRB or its degree of phosphorylation. However,
this last issue is unlikely since the antibody used (Rb-PMG3-
245) detects both hypo- and hyperphosphorylated pRB prod-
ucts. In addition, while pRB expression in normal cells has
been felt to be ubiquitous, recent analyses in normal tissue
have documented low to undetectable pRB levels in associa-
tion with specific cell types, including fibroblasts (Szekely et
al., 1992; Cordon-Cardo and Richon, 1994). It is then
reasonable to postulate that well differentiated soft-tissue
sarcomas with a low proliferative index have low to undetec-
table pRB expression, below the threshold of immunohis-
tochemistry. It is interesting to note that the number of
low-grade tumours displaying a homogeneous pRB
phenotype decreased with disease progression from 30% in
primary sarcomas to 18% in local recurrences. This change
was paralleled with a concurrent increase in the percentage of
pRB heterogeneous lesions. This inverse relationship between
tumour progession and pRB expression was not demon-
strated in the high-grade tumours. In those cases, the extent
of heterogeneous and undetectable pRB levels was similar in
primary and metastatic lesions.
In our original study we analysed the survival of 44
patients with primary high-grade bone and soft-tissue sar-
comas from all age groups. We found that survival of
patients with altered pRB levels was significantly shorter at
24 months than patients whose tumours had homogeneous
pRB staining. In the present study we observed similar
differences at 18 and 24 months of follow-up between survial
and pRB-positive vs pRB-negative cases, as in our initial
study. However, beyond 24 months pRB expression did not
appear to influence the survival of adult patients with
primary high-grade soft-tissue sarcomas. Given the current
survival results, we updated the follow-up of our previous
data and reanalysed the results to test the durability of our
early differences (Figure 2). At approximately 24 months the
three curves begin to come together and the differences were
no longer observed. It is not an unknown biological observa-
tion to see early differences lose their significance over time.
For example, the contribution of various clinicopathological
features of patients with sarcoma can vary according toRB expression in adult soft-tissue sarcomas
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Figure 2 Updated follow-up analysis of pRB alterations in
primary sarcomas according to the study of Cance et al. (1990).
0, 0-19%; A, 20-79%; 0, 80-100%.
duration of follow-up. Tumour grade is the dominant factor
in early metastases, whereas the influence of this variable on
the development of late metastases is equivalent (Gaynor et
al., 1993). The early survival advantage of the patients with
pRB positive sarcomas may reflect a delay in metastatic
potential which diminishes with time. Other important
differences between the two studies are the exclusion of
osteosarcomas and paediatric sarcomas, as well as the more
than doubling of the sample size. Bone and paediatric sar-
comas are known to have high response rates to
chemotherapy. Consequently, the prognosis of these patients
has been dramatically improved by the addition of adjuvant
chemotherapy (Link et al., 1991). This is not the case in
adults with extremity soft-tissue sarcomas (Mazanet and Ant-
man, 1991). As for the number of patients studied, the
potential for 'type II' statistical error is now reduced com-
pared with our original study, in which conclusions were, in
essence, based on the survival of 13 patients.
In summary, based on data from this study we cannot
ascribe prognostic significance to alterations in RB gene exp-
ression in adult soft-tissue sarcomas. Given the high percen-
tage of abnormal RB gene expression in primary low- and
high-grade sarcomas, it appears that alterations in the expres-
sion of this gene occur both frequently and early in the
pathogenesis of soft-tissue sarcomas. Our data suggest that,
in adult soft-tissue sarcomas, alterations of the RB gene may
be more important in tumorigenesis or early tumour progres-
sion than in late disease stages. More studies are required
comparing RB and other tumour-suppressor gene abnor-
malities developing in well-characterised groups of patients
affected with soft-tissue sarcomas in order to evaluate their
critical role as tumour markers able to stratify patients in
prognostic categories.
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